Applied Therapeutics Inc · Q3 2020 earnings

Briefing

Reported financial results for the third quarter ended September 30, 2020.

Applied Therapeutics reported on their Diabetic Cardiomyopathy program, with continued enrollment in the ARISE-HF global Phase 3 registrational study. They are preparing for new rare disease clinical programs in SORD Deficiency and PMM2-CDG, planned to start in 2021, and are collaborating with the FDA to restart the ACTION-Galactosemia Kids pediatric study.

• Continued enrollment in the ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy.
• On track to initiate rare disease franchise expansion programs in SORD Deficiency and PMM2-CDG studies in the first half of 2021.
• Continued collaboration with FDA to restart the ACTION-Galactosemia Kids pediatric study.
• Presented new data on AT-001 mechanism of action and improvement in cardiac energetics.

Headline financials

Revenue & EPS history

The company is preparing for new rare disease clinical programs in SORD Deficiency and PMM2-CDG, planned to start in 2021, and are collaborating with the FDA to restart the ACTION-Galactosemia Kids pediatric study.